Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
25 Settembre 2023 - 7:00AM
Valneva Announces New IXIARO® Supply Contract with the U.S.
Government Worth a Minimum of $32 Million
Saint Herblain
(France),
September 25,
2023 – Valneva SE (Nasdaq: VALN; Euronext
Paris: VLA), a specialty vaccine company, today announced the
signing of a new $32 million contract with the United States (U.S.)
Department of Defense (DoD) for the supply of its Japanese
encephalitis (JE) vaccine, IXIARO®.
Under this new one-year contract, the DoD will
buy a minimum of $32 million worth of IXIARO® vaccines and has the
possibility to purchase additional doses during the coming twelve
months. Deliveries will commence immediately.
Dipal Patel,
Chief Commercial Officer
of Valneva commented, “We are excited to continue
our long-term relationship with the DoD. The U.S. military has
trusted IXIARO® for over ten years to help protect military
personnel, their families, civilian government service personnel,
and government contractors from this potentially deadly
disease.”
IXIARO® is the only JE vaccine approved by the
U.S. Food and Drug Administration (FDA), having been developed
through a cooperative research and development agreement with the
Walter Reed Army Institute of Research. In the U.S., Valneva
markets and distributes IXIARO® directly to the military and
private travel market.
About IXIARO®/JESPECT®
Valneva’s Japanese encephalitis vaccine is
indicated for active immunization for the prevention of the disease
for people who travel to, or live in, endemic areas. It has
received marketing approval in the U.S., Europe, Canada, Hong Kong,
Singapore, and Israel under the trade name IXIARO® and in Australia
and New Zealand where it is marketed as JESPECT®. It is the only
vaccine available to the U.S. military for Japanese Encephalitis.
IXIARO® is approved for use in individuals two months of age and
older in the U.S. and EU member states, Canada, Norway,
Liechtenstein, Iceland, Singapore, Hong Kong, Japan, the Republic
of Korea and Israel. In all other licensed territories,
IXIARO®/JESPECT® is indicated for use in persons aged 18 years or
more.
About Japanese Encephalitis
Japanese encephalitis is a deadly infectious
disease found mainly in Asia. About 70,000 cases of JE are
estimated to occur in Asia each year, although the actual number of
cases is likely much higher due to underreporting in rural areas.
JE is fatal in approximately 30 percent of those who show symptoms,
and leaves half of survivors with permanent brain damage. The
disease is endemic in Southeast Asia, India and China, a region
with a population of more than three billion. In 2005, JE killed
more than 1,200 children in only one month during an epidemic
outbreak in Uttar Pradesh, India, and Nepal.
About Valneva SEWe are a
specialty vaccine company focused on the development, manufacturing
and commercialization of prophylactic vaccines for infectious
diseases. We take a highly specialized and targeted approach to
vaccine development by focusing on vaccine solutions addressing
unmet medical needs to ensure we can make a difference to peoples’
lives. We apply our deep understanding of vaccine science,
including our expertise across multiple vaccine modalities, and our
established vaccine development capabilities, to develop vaccines
against diseases which are not yet vaccine-preventable, or for
which there are limited effective treatment options. Today, we are
leveraging our expertise and capabilities to rapidly advance a
broad range of vaccines into and through the clinic, including
candidates against the chikungunya virus and Lyme disease.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP Global Communications & European Investor
RelationsM +33 (0)6 4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
|
|
|
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to possible additional orders of IXIARO®. In
addition, even if the actual results or development of Valneva are
consistent with the forward-looking statements contained in this
press release, those results or developments of Valneva may not be
indicative of their in the future. In some cases, you can identify
forward-looking statements by words such as "could," "should,"
"may," "expects," "anticipates," "believes," "intends,"
"estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, changing needs
of the U.S. military, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made during this presentation will in
fact be realized. Valneva is providing the information in these
materials as of this press release and disclaim any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
- 2023_09_25_IXIARO_New_DoD_Contract_PR_EN_Final
Grafico Azioni Valneva (LSE:0OB3)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Valneva (LSE:0OB3)
Storico
Da Set 2023 a Set 2024